Main Industry
Biotechnology
Main Product/Service
The company’s lead product, OBI‑858, is a novel 760 kDa botulinum toxin derived from Clostridium botulinum type A. OBI‑858 has successfully completed a Phase I clinical trial, demonstrating excellent safety, tolerability, and preliminary efficacy in reduc
Founded Year
2020
Unified Business No.
82943056
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,072,292,500 (NT$)
Location of Company
Taiwan
, Hsinchu County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
OBIGEN Pharma, also known as Ding‑Jin Biotech, is the first Taiwan-based company dedicated to the research, development, and manufacturing of its own botulinum toxin products. The company operates under stringent safety and quality standards, maintaining PIC/s‑GMP–certified raw‑material and sterile production facilities.
